On February 23, 2024, Health Canada published a Notice advising that it was making its review process for generic drug submissions more transparent. Specifically, for generic drug submissions accepted into review on or after April 1, 2024, Health Canada will start disclosing: (i) the year and month that the submission was accepted for review; and
More Posts
Dormant drug status can trigger generic access to an alternate Canadian Reference Product
Florida approved to import Canadian prescription drugs
Drug reimbursement: CADTH publishes procedures on time-limited reimbursement
Drug advertising: Updated guidance from Health Canada on the distinction between advertising and other activities for health products
Drug price negotiations: pCPA consulting on a Temporary Access Process (pTAP)
Health Canada releases updated Certificate of Supplementary Protection guidance
Canada announces its first-ever national strategy for drugs for rare diseases
Ontario introduces biosimilar transition policy
Generic not required to address Patent Register when reference innovator drug is no longer marketed in Canada
Subscribe: Subscribe via RSS
Firm/Org